ALLN-177, oral enzyme therapy for hyperoxaluria

PURPOSE: To evaluate the potential of ALLN-177, an orally administered, oxalate-specific enzyme therapy to reduce urine oxalate (UOx) excretion in patients with secondary hyperoxaluria. METHODS: Sixteen male and female subjects with both hyperoxaluria and a kidney stone history were enrolled in an o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lingeman, James E., Pareek, Gyan, Easter, Linda, Pease, Rita, Grujic, Danica, Brettman, Lee, Langman, Craig B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2019
Materias:
Urology - Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459785/
https://www.ncbi.nlm.nih.gov/pubmed/30783888
http://dx.doi.org/10.1007/s11255-019-02098-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459785/
https://www.ncbi.nlm.nih.gov/pubmed/30783888
http://dx.doi.org/10.1007/s11255-019-02098-1

Ejemplares similares